Overview

A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)

Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess disability in anemic patients over the age of 65 who have kidney disease and are receiving weekly PROCRIT® (Epoetin Alfa, a glycoprotein that stimulates red blood cell production).
Phase:
Phase 4
Details
Lead Sponsor:
Ortho Biotech Products, L.P.
Treatments:
Epoetin Alfa